Overview

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

Status:
Unknown status

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor

Phase:

Phase 2

Details

Lead Sponsor:

Chinese Academy of Medical Sciences

Treatments:

Dacarbazine
Tegafur
Temozolomide
Thalidomide